ScinoPharm Taiwan, in collaboration with pharmaceutical products manufacturer CVie Therapeutics, has launched a discovery and development collaboration to identify the new generation compound to heart failure treatment Istaroxime.

CVie's Istaroxime treatment is currently in late Phase IIb trials in Italy and China and is a luso-inotropic agent under development to treat acute decompensated heart failure.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Istaroxime has a dual mode of action, combining inotropic (myocyte contraction) and lusotropic (myocyte relaxation) effects.

ScinoPharm CEO Dr Yung Fa Chen said: “This collaboration with CVie signals ScinoPharm's strategic move into the new drug development field. From both scientific and business perspectives, we are very excited for this alliance.”

"This collaboration with CVie signals ScinoPharm's strategic move into the new drug development field."

Once recognised, the new generation compound will possess oral bioavailability while retaining Istaroxime's unique dual luso-inotropic function.

See Also:

The successful candidate for the compound is expected to be useful for patients with both acute and chronic heart failure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CVie president and COO Dr Lit-Fui Lau said: “The partnership between ScinoPharm and CVie will take advantage of the strengths of both companies toward the discovery of the orally available Istaroxime analogs for the treatment of acute and chronic heart failure.”

Under the deal, ScinoPharm will offer medicinal chemistry design and synthesis, and CVie will apply its comprehensive biological knowledge to screen and identify the new candidate.

Once the new compound enters the clinical development phases, ScinoPharm will become the primary chemistry, manufacturing, and controls (CMC) service provider in order to provide material for clinical phases and beyond.